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Mutations in the IL23R gene are linked to
inflammatory bowel disease susceptibility. Experi-
mental models have shown that interleukin-23
(IL-23) orchestrates innate and T cell-dependent
colitis; however, the cell populations it acts on to
induce intestinal immune pathology are unknown.
Here, using Il23r/ T cells, we demonstrated that
T cell reactivity to IL-23 was critical for development
of intestinal pathology,but not for systemic inflamma-
tion. Through direct signaling into T cells, IL-23 drove
intestinal T cell proliferation, promoted intestinal Th17
cell accumulation, and enhanced the emergence of
an IL-17A+IFN-g+ population of T cells. Furthermore,
IL-23R signaling in intestinal T cells suppressed the
differentiation of Foxp3+ cells andT cell IL-10produc-
tion. Although Il23r/ T cells displayed unimpaired
Th1 cell differentiation, these cells showed impaired
proliferation and failed to accumulate in the intestine.
Together, these results highlight the multiple func-
tions of IL-23 signaling in T cells that contribute to
its colitogenic activity.
INTRODUCTION
The inflammatory bowel diseases (IBDs), comprising Crohn’s
Disease (CD) and ulcerative colitis (UC), are severe inflammatory
disorders of the gastrointestinal tract whose incidence are on
the increase (Xavier and Podolsky, 2007). Current therapeutic
targeting of proinflammatory cytokines such as TNF-a has
proved to be effective, but can lead to deleterious side
effects and approximately one-third of patients fail to respond
(Podolsky, 2002). These results highlight the need for the identi-
fication of new and more specific therapeutic targets for the
treatment of IBDs.
Interleukin-23 (IL-23), a heterodimeric cytokine comprising
IL-12p40 and IL-23p19 (Oppmann et al., 2000), is nowwell docu-
mented to be critical in the pathogenesis of a number of murine
models of autoimmune and inflammatory conditions such asexperimental autoimmune encephalomyelitis (EAE), collagen
induced arthritis (CIA), and intestinal inflammation (Cua et al.,
2003; Hue et al., 2006; Kullberg et al., 2006; Murphy et al.,
2003; Uhlig et al., 2006b; Yen et al., 2006). The activity of IL-23
is more prominent in the mucosal tissues, such as the intestine,
than in the systemic immune compartment enhancing its attrac-
tiveness as a therapeutic target in IBD (Uhlig et al., 2006b).
A functional receptor for IL-23 (IL-12Rb1 and IL-23R) (Parham
et al., 2002) is expressed on ab and gd T cells as well as innate
leukocytes (Awasthi et al., 2009; Parham et al., 2002) and IL-23
signaling is mediated predominantly by the signal transducer
and activator of transcription 3 (STAT3) (Parham et al., 2002).
The functional activity of IL-23 has been primarily linked to
the T helper 17 (Th17) cell subset (McGeachy and Cua, 2008;
O’Shea and Murray, 2008). Development of Th17 cells is
mediated by a combination of the cytokines TGF-b and IL-6,
IL-21, or IL-1, through the molecular activity of the transcription
factors RORgt, RORa, IRF-4, AHR, and STAT3 (Dong, 2008;
Ahern et al., 2008). Th17 cells are enriched for expression of
Il23r (Langrish et al., 2005) and IL-23 plays an important role in
the sustenance of Th17 cell responses in vivo (Mangan et al.,
2006; McGeachy et al., 2009). However, the cellular and molec-
ular pathways through which IL-23 promotes inflammatory
responses in vivo are poorly characterized.
Human IBD is associated with increased expression of IL-23
and Th17 cell signature cytokines such as IL-17A and IL-17F
(Ahern et al., 2008). Furthermore, genome-wide association
studies have identified single-nucleotide polymorphisms
(SNPs) in IL23R and the STAT3 loci as CD susceptibility regions
(Burton et al., 2007; Duerr et al., 2006). Interestingly, IL23R vari-
ants are risk factors for both CD and UC and thus contribute to
both types of IBD (Duerr et al., 2006). Together, these data high-
light IL23R as a key player in the pathogenesis of IBD.
Indeed, neutralization of IL-23 has been shown to ameliorate
and cure colitis in a number of mouse models of IBD, including
colitis induced by naive T cell transfer (Elson et al., 2007; Hue
et al., 2006) in which the role for IL-23 has been linked to control
of Th17 cell responses (Leppkes et al., 2009). Early studies also
revealed a key role for Th1 cell responses in T cell-mediated
colitis as both T-bet deficiency in T cells (Neurath et al., 2002)
and blockade of IFN-g-inhibited colitis (Powrie et al., 1994).
Genetic ablation of Il23a rather surprisingly revealed that IL-23
rather than IL-12 drives the Th1-IFN-g inflammatory axis in theImmunity 33, 279–288, August 27, 2010 ª2010 Elsevier Inc. 279
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Figure 1. IL-23R Expression on T Cells Is
Required for Intestinal but Not Systemic
Inflammation
C57BL.6.Rag1/ mice were transferred with 4 3
105 CD4+CD45RBhi T cells from WT or Il23r/
donors. Mice were sacrificed when recipients of
WT T cells developed clinical signs of disease
(9 weeks after transfer) and assessed for intes-
tinal and systemic inflammation.
(A) Colitis scores.
(B) Representative photomicrographs of mid colon
sections.
(C) Total CD4+ T cells in colon.
(D) Total splenocytes.
(E) Total CD4+ T cells in spleen.
(F) Representative photomicrographs of liver
sections.
(G) Expression of cytokine mRNA in colon tissue
homogenates, normalized to Hprt.
(H) Concentration of cytokines in colon tissue
homogenates, normalized to total protein.
Data represent pooled results from two to three
independent experiments. Bars represent the
mean, error bars represent the SEM, and each
symbol represents an individual mouse, n = 11–16
(WT T cells), n = 13–18 (Il23r/ T cells), n = 3–13
(Controls; Ctl.). Statistical significance was deter-
mined with the Mann-Whitney test.
Immunity
Direct IL-23 Signals into T Cells Drive Colitisintestine (Hue et al., 2006), although the mechanisms by which
IL-23 promotes Th1 cell responses in vivo is not known.
Pathogenic effector T cell responses in the intestine are nor-
mally prevented by the presence of regulatory (Treg) T cells
derived from both thymic and peripherally induced Foxp3+
Treg (iTreg) cells (Izcue et al., 2009). It has been demonstrated
that IL-23 drives intestinal inflammation in part through the inhi-
bition of iTreg cell development in the intestine (Izcue et al.,
2008), but precisely how IL-23 controls this process is still poorly
understood. IL-23 is also known to drive intestinal inflammation
in Rag1/ mice infected with Helicobacter hepaticus in the
absence of T or B cells (Buonocore et al., 2010; Hue et al.,
2006), and this has recently been linked to an IL-23-responsive
innate lymphoid population (Buonocore et al., 2010). Thus,
IL-23 can promote intestinal pathogenesis via direct stimulation
of the innate immune system raising the possibility that the
effects on T cell responses are indirect through the activity of
IL-23 on innate immune cells.280 Immunity 33, 279–288, August 27, 2010 ª2010 Elsevier Inc.Here, we have utilized Il23r/ mice to
assess the role of IL-23R signaling in
T cells in the development of chronic
colitis. Our results showed that IL-23
drives intestinal but not systemic inflam-
mation through direct effects on T cells.
IL-23 signals into T cells promoted their
proliferation and accumulation in the
colon and favored the emergence of an
IL-17A+IFN-g+ population of T cells
while inhibiting Foxp3 expression. These
results indicate that through its actions
on T cells, IL-23 modulates both inflam-matory and regulatory arms of Th cell responses to orchestrate
intestinal inflammation.
RESULTS
IL-23R Expression on T Cells Is Required for Intestinal
but Not Systemic Inflammation
To assess the role of IL-23R expression on T cells in the develop-
ment of colitis, we transferred CD4+CD45RBhi cells isolated from
wild-type (WT) or Il23r/ mice into B and T cell-deficient
Rag1/mice, with the latter allowing us to restrict IL-23 respon-
siveness to the innate immune compartment. As previously
described (Powrie et al., 1993; Read et al., 2000), WT
CD4+CD45RBhi T cells vigorously expand upon transfer and
induce both a systemic inflammatory response and severe colitis
(Figures 1A–1F). By contrast, the majority of mice restored
with Il23r/ CD4+ T cells developed only minimal intestinal
inflammation with little cellular infiltrate or epithelial hyperplasia
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Figure 2. IL-23 Regulates Intestinal Th Cell Responses via Direct
Effects on T Cells
C57BL.6.Rag1/ mice were transferred with 4 3 105 CD4+CD45RBhi T cells
fromWT or Il23r/ donors and sacrificed when recipients of WT T cells devel-
oped clinical signs of disease (9 weeks after transfer). IL-17A, IFN-g, and
Foxp3 amounts in T cells from various tissues were assessed by intracellular
flow cytometry after in vitro restimulation with PMA and ionomycin.
(A) Representative flow cytometry plots of CD4+ T cells from the spleen, MLN,
and colon. Numbers in quadrants represent frequencies.
(B) Frequencies of IL-17A+ and/or IFN-g+ T cells in the spleen,MLN, and colon.
(C) Total numbers of IL-17A+ and/or IFN-g+ CD4+ T cells in the colon.
(D) Frequencies of Foxp3+ CD4+ T cells in the spleen, MLN, and colon.
(E) Total number of Foxp3+ CD4+ T cells in the colon.
Data represent pooled results from two to three independent experiments,
bars represent the mean, error bars represent the SEM, and each symbol
Immunity
Direct IL-23 Signals into T Cells Drive Colitis(Figures 1A and 1B). Transfer of Il23r/ T cells led to an 80%
reduction in the number of CD4+ T cells in the colon compared
to WT controls illustrating an important requirement for IL-23R
signaling in T cells for their ability to accumulate and orchestrate
an inflammatory response in the intestine (Figure 1C).
Despite the impaired mucosal inflammation, transfer of
Il23r/ T cells led to a potent systemic inflammatory response.
Indeed, compared with recipients of IL-23R-sufficient T cells, we
observed no difference in splenomegaly (Figure 1D), splenic
T cell accumulation (Figure 1E), hepatic infiltrates (Figure 1F),
serum concentrations of proinflammatory cytokines and chemo-
kines, such as IL-6, MCP-1, TNF-a, and IFN-g (Figure S1A
available online), or weight loss (Figure S1B) in recipients of
Il23r/ T cells. Serum IL-22 concentrations were significantly
reduced in the absence of IL-23R expression on T cells, indi-
cating a role for IL-23 in the systemic production of certain
Th17 cell-associated cytokines. By contrast, the attenuated
inflammation observed in the intestine of recipients of Il23r/
T cells was associated with reduced expression of a number of
Th17 cell signature cytokines including Il17a, Il21, and Il22, as
well as in the Th17 cell master transcription factor Rorc
(Figure 1G). However, unlike the systemic immune compart-
ment, the intestines of recipients of Il23r/ T cells had reduced
concentrations of more general inflammatory cytokines such as
TNF-a, MCP-1, and IFN-g (Figure 1H).
Together, these data suggest a tissue-specific role for IL-23R
signaling in T cells for intestinal inflammation, whereas the
systemic inflammatory response is largely independent of the
direct effects of IL-23 on T cells.IL-23 Regulates Intestinal Th Cell Responses through
Direct Effects on T Cells
T cell transfer colitis is associated with the accumulation of Th1
and Th17 cells in the intestine (Hue et al., 2006; Izcue et al.,
2008). To analyze the direct effects of IL-23R signals on Th cell
subset differentiation in the intestine, we isolated cells from
the spleen, mesenteric lymph node (MLN), and colon of mice
transferred with WT or Il23r/CD4+ T cells and performed intra-
cellular flow cytometric analysis of IL-17A and IFN-g expression.
Three distinct populations emerged in Rag1/ recipients of WT
CD4+ T cells: IL-17A+IFN-g, IL-17AIFN-g+, and IL-17A+IFN-g+
(Figure 2A).We found significant reductions in the IL-17A+IFN-g
population of T cells in the spleen and MLN but not in the intes-
tine of recipients of Il23r/ T cells (Figure 2B). However, the
IL-17A+IFN-g+ T cell population was significantly reduced in all
compartments, including the intestine, in recipients of Il23r/
T cells, indicating a role for IL-23 in promoting this effector cell
phenotype (Figure 2B). By contrast, there was no difference in
the frequency of IL-17AIFN-g+ T cells in any compartment of
Rag1/ mice that received WT or Il23r/ T cells (Figure 2B),
demonstrating that Il23r/ T cells were not defective in their
ability to differentiate into IFN-g producing Th1 cells. However,
there was a reduced number of all three effector populations,
including IL-17AIFN-g+ T cells in the intestine of mice trans-
ferred with Il23r/ T cells (Figure 2C). Thus, although IL-23represents an individual mouse. Statistical significance was determined with
the Mann-Whitney test, n = 11–16 (WT), n = 13–18 (Il23r/).
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Figure 3. IL-23 Directly Promotes Intestinal
T cell Proliferation
(A and B) C57BL.6.Rag1/mice were transferred
with 43 106 CFSE-labeled CD4+CD45RBhi T cells
from WT or Il23r/ donors and sacrificed 12 days
after transfer. (A) Total CD4+ T cell numbers and (B)
representative flow cytometry plots showing CFSE
dilution profiles of T cells from the spleen and
colon are presented.
(C–E) C57BL.6.Rag1/ mice were transferred
with 4 3 105 CD4+CD45RBhi T cells from WT or
Il23r/ donors and sacrificed when recipients of
WT T cells developed clinical signs of disease
(6 weeks after transfer). IL-17A, IFN-g, and Ki67
expression in CD4+ T cells from the colon were as-
sessed by intracellular flow cytometry after in vitro
restimulation with PMA and ionomycin. (C) Fre-
quencies, (D) representative flow cytometric plots
(numbers in gate represent frequencies), and
(E) total numbers of IL-17A+IFN-gKi-67+, IL-17A+
IFN-g+Ki-67+, and IL-17AIFN-g+Ki-67+ CD4+
T cells in the colon. Data represent pooled results
from two independent experiments (A and B) or of
a single experiment (C–E), bars represent the
mean, error bars represent the SEM, and each
symbol represents an individual mouse. Statistical
significance was determined with the Mann-Whit-
ney test, n = 4-11 (WT), n = 5-11 (Il23r/).
Immunity
Direct IL-23 Signals into T Cells Drive Colitiswas not required for Th1 cell development, the expansion and/or
accumulation of this population was facilitated by an IL-23-
driven T cell response.
Previously, we have shown that IL-23 promotes intestinal
inflammation in part through its ability to antagonize iTreg cell
development in the intestine (Izcue et al., 2008). Whether this is
a direct or indirect activity of IL-23 on T cells was not established.
We observed that Il23r/ T cells gave rise to higher frequencies
of Foxp3+ T cells in the intestine when transferred into Rag1/
recipients as compared to their WT counterparts (Figure 2D),
although total numbers were not significantly different
(Figure 2E). This suggests that IL-23-driven Foxp3 inhibition
can be mediated by the direct activity of IL-23 on T cells.
IL-23 Controls T Cell Accumulation in the Intestine
through Effects on Proliferation
The failure of Il23r/ T cells to accumulate in the inflamed colon
could reflect a homing defect or a failure to proliferate and/or
survive in the colon. To assess the ability of Il23r/ T cells to
home to the colon, we transferred Rag1/ mice with CFSE-282 Immunity 33, 279–288, August 27, 2010 ª2010 Elsevier Inc.labeled WT or Il23r/ CD4+ T cells and
sacrificed recipients 12 days after trans-
fer, prior to the onset of inflammation.
We found equal numbers of T cells in
the spleen and colon at this time point,
indicating that Il23r/ CD4+ T cells were
not defective in their ability to migrate to
the intestine (Figure 3A). In addition,
Il23r/ CD4+ T cells are not impaired in
their ability to express the chemokine
receptors Ccr6, Cxcr3, Ccr2, and Ccr5(Figure S2A). Furthermore, both populations of T cells had
diluted CFSE to the same degree (Figure 3B), demonstrating
that Il23r/ CD4+ T cells did not display an early impairment in
division once present in the colon. Next, we assessed the prolif-
erative capacity of WT and Il23r/ T cells later in the response.
Thus, Rag1/ mice were transferred with WT or Il23r/ CD4+
T cells and sacrificed upon clinical signs of inflammation in WT
transferred recipients. Proliferation was assessed by measuring
the frequency of Ki-67+ CD4+ T cells with intracellular flow
cytometry. Under these conditions, we found reduced frequen-
cies of Ki-67+ cells among all three effector Th cell populations
in the colon of Il23r/ T cell-transferred Rag1/ recipients
compared to those recovered from WT T cell-transferred recipi-
ents (Figures 3C and 3D). In Il23r/ T cell-transferredmice, there
were also marked reductions in the total number of proliferating
effector Th populations (IL-17A+IFN-g, IL-17AIFN-g+, and
IL-17A+IFN-g+) in the colon (Figure 3E). By contrast, equivalent
frequencies of Ki-67+ T cells were observed in WT and IL23r/
effector T cell populations recovered from the spleen (Figure S2B
and S2C). Together, these data indicate that IL-23 is an
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Figure 4. IL-23 Controls T cell Accumulation in the Intestine via
a Cell-Extrinsic Mechanism
C57BL.6.Rag1/ mice were transferred with 1:1 mixtures of CD45.2 (WT) +
CD45.2+ (WT) or CD45.2 (WT) + CD45.2+(Il23r/) CD4+CD45RBhi T cells.
Mice were sacrificed upon development of clinical signs of inflammation
(8 weeks) and populations of T cells were identified on the basis of the
expression of CD45.2.
(A) Ratio of CD45.2+/CD45.2 CD4+ T cells in colon. Data represent pooled
results from two independent experiments; n = 15 (WT + WT), n = 12 (WT +
Il23r/). Bars represent the mean ± SEM.
(B and C) Sublethally irradiated C57BL.6.Rag1/ mice were reconstituted
with 1:1 mixtures of CD45.2 (WT) + CD45.2+ (WT) or CD45.2 (WT) +
CD45.2+(Il23r/) bone marrow cells. Ratio of CD45.2+/CD45.2 T cells
recovered from the colon during steady state (B) or during colitis induced by
infection with Helicobacter hepaticus plus treatment with a blocking IL-10R
mAb (C). Data represent results from a single experiment; n = 5–7 (WT +
WT), n = 5–7 (WT + Il23r/ T cells). Bars represent the mean ± SEM.
Immunity
Direct IL-23 Signals into T Cells Drive Colitisimportant proliferative signal for colonic T cells, and such a
finding may directly account for the impaired ability of Il23r/
T cells to accumulate in the intestine.
IL-23 Controls T Cell Accumulation in the Intestine
through a Cell-Extrinsic Mechanism
Next, we assessed the ability of Il23r/ T cells to compete with
WT T cells under inflammatory conditions. Using a cotransfer
system (Figure S3A), we administered an equal number of con-
genic CD45.2 WT and CD45.2+ Il23r/ naive CD4+ T cells
into Rag1/ recipients. For a control, we also transferred a 1:1
ratio of CD45.2 and CD45.2+ WT naive CD4+ T cells and al-
lowed mice to develop wasting disease and colitis. Assessment
of the relative contribution of CD4+ cells in the MLN and colon
that derived from the transferred CD45.2 or CD45.2+ T cell pop-
ulations revealed that IL-23R-deficient CD4+ T cells were indis-
tinguishable from WT CD4+ T cells in their ability to accumulate
in the MLN and inflamed colon of colitic mice (Figure S4 and
Figure 4A). These results indicate that the presence of IL-23R-
sufficient T cells and their subsequent downstream inflammatory
signals overcomes the requirement for cell-intrinsic IL-23R
signaling for T cell accumulation in the intestine.
Although the T cell transfer model offers a unique opportunity
to study the contributions of various cell types to intestinal
immune pathology, the increased T cell proliferation after trans-
fer to lymphopenic Rag1/ hosts may overcome a cell intrinsic
role for IL-23R in intestinal accumulation of T cells. To test this,
we generated mixed bone marrow chimeras by using a 1:1 ratio
of CD45.2WTbonemarrowwith either CD45.2+WT or CD45.2+
Il23r/ bone marrow (Figure S3B) to assess the capacity of
Il23r/ T cells to compete for accumulation in the colon in
a lymphocyte-replete host. As shown (Figure 4B), even under
homeostatic conditions, in the presence of WT T cells, Il23r/
T cells showed no deficiency in their capacity to accumulate in
the colon and to compete with WT T cells for this niche. To
test whether this was also the case during intestinal inflamma-
tion, we infected similarly generated chimeras with the intestinal
pathogenHelicobacter hepaticus and treated themwith a block-
ing IL-10RmAb, which we have previously shown leads to IL-23-
dependent colitis and typhlitis (Kullberg et al., 2006). In these
mixed chimeras, under inflammatory conditions, we found a
similar contribution to the CD4+ T cell pool in the colon from
WT and Il23r/ T cells (Figure 4C). These results confirm our
observations in the T cell transfer model and show that the pres-
ence of IL-23R+ T cells is sufficient to drive the accumulation of
Il23r/ T cells in the gut by a cell-extrinsic mechanism. Thus,
Il23r/ T cells are not intrinsically defective in their ability to
compete and accumulate under inflammatory conditions, but
require an IL-23-driven T cell response to do so. Therefore,
although IL-23R signals in T cells are required for their effective
accumulation, the effects are not cell autonomous.
IL-23 Regulates the Balance between Effector and
Regulatory Th Cells through Cell-Intrinsic Mechanisms
Our transfers of Il23r/ T cells into Rag1/mice revealed a role
for IL-23R signaling in T cells in influencing the balance of Th17
and Foxp3+ Treg cells in the intestine. However, we could not
rule out the possibility that the decrease in IL-17A+IFN-g+
T cells and the increase in Foxp3+ Treg cell frequency weobserved after transfer of Il23r/ T cells was secondary to the
lack of inflammation in this setting. To circumvent this, we
utilized the cotransfer system described above in which
cotransfer of WT and Il23r/ T cells led to intestinal inflamma-
tion and similar accumulation of IL-23R-sufficient and IL-23R-
deficient T cells. Consistent with our observations in single-
transfer experiments (Figure 2B), in cotransfer experiments we
observed equivalent differentiation of IL-17A+IFN-g and
IL-17AIFN-g+ cells among the WT and Il23r/ populations of
T cells in the colon (Figures 5A–5C). By contrast, the frequency
of IL-17A+IFN-g+ cells was significantly reduced among the
Il23r/ pool of CD4+ T cells in the intestine (Figures 5A and
5D), demonstrating a cell-intrinsic role for IL-23 in the in vivo
modulation of the Th17 effector cell phenotype. Thus, even
under inflammatory conditions in which Il23r/ T cellsImmunity 33, 279–288, August 27, 2010 ª2010 Elsevier Inc. 283
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Figure 5. IL-23 Modulates Th17 Cell Pheno-
type via a Direct Cell-Intrinsic Mechanism
C57BL.6.Rag1/ mice were transferred with 1:1
mixtures of CD45.2 (WT) + CD45.2+ (WT), or
CD45.2 (WT) + CD45.2+(Il23r/) CD4+CD45RBhi
T cells. Mice were sacrificed upon development
of clinical signs of inflammation (8 weeks) and
IL-17A and IFN-g levels in colonic CD4+ T cells
were assessed by intracellular flow cytometry after
in vitro restimulation with PMA and ionomycin.
(A) Representative flow cytometry plots of CD4+
T cells isolated from the colon; numbers in quad-
rants represent frequencies.
(B–D) Frequencies of IL-17A+ and/or IFN-g+ CD4+
T cells in the colon of cotransferred mice.
Data represent pooled results from two indepen-
dent experiments. Bars represent the mean;
each symbol represents an individual mouse.
Statistical significance was determined with the
Mann-Whitney test, n = 12 (WT + WT), n = 10
(WT + Il23r/).
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Direct IL-23 Signals into T Cells Drive Colitisaccumulate normally in the intestine, their differentiation into IL-
17A+IFN-g+ CD4+ T cells is impaired, indicating that this is
directly controlled by cell-intrinsic IL-23R signals.
Analysis of Foxp3 expression in these cotransfer experiments
also revealed a cell-intrinsic role for IL-23R signaling in T cells in
the inhibition of Foxp3 expression. As shown (Figures 6A
and 6B), in the inflamed colon there was a 2- to 3-fold increase
in the frequency of Foxp3+ cells among Il23r/ T cells compared
to cotransferredWT T cells. Given that only a very low proportion
of naive T cells differentiated into Foxp3+ iTreg cells after transfer
into Rag1/ recipients, we sought to confirm these findings in
lymphocyte-replete hosts in the presence or absence of intes-
tinal inflammation. We performed similar analysis of Foxp3
expression in the mixed bone marrow chimeras described
above, both under steady state conditions and in circumstances
where intestinal inflammation was induced by infection with
H. hepaticus with concomitant administration of a blocking
IL-10R mAb. We again observed a significant increase in the
frequency of Foxp3+ cells derived from Il23r/ T cells compared
to WT T cells under both homeostatic (Figure 6C) and inflamma-
tory conditions (Figure 6D). Together, these data indicate that
IL-23R signaling in T cells is a tissue-specific modulator of
T cell function in the intestine where it negatively regulates Foxp3
expression in a cell-intrinsic fashion.
Despite the increased frequencies of Treg cells observed in
the colon of mice transferred with Il23r/ T cells, the incidence
and severity of colitis in mice receiving a mixture of CD45.2WT
plus CD45.2+ WT or CD45.2 WT plus CD45.2+ Il23r/ T cells
was almost identical, indicating that Il23r/ T cells do not
possess dominant suppressive activity (Figure 6E). We therefore
assessed whether the regulatory properties of Il23r/ T cells,
specifically IL-10 production, were altered in the cotransfer
system compared to single transfers. Consistent with reduced
intestinal inflammation (Figures 1A and 1B), colonic Il23r/
T cells from single-transfer experiments expressed significantly
greater amounts of Il10 mRNA and secreted higher amounts of
IL-10 protein than WT T cells (Figure 6F). By contrast, Il23r/284 Immunity 33, 279–288, August 27, 2010 ª2010 Elsevier Inc.T cells isolated from the colon of mice cotransferred with WT
cells did not exhibit this enhanced IL-10 expression and secre-
tion (Figure 6F). Thus, in the presence of IL-23R-responsive
WT T cells there is a reduction in the ability of Il23r/ T cells to
produce IL-10, which may explain the development of colitis in
mice given amixture ofWT and Il23r/ T cells, despite increases
in the percentage of Foxp3+ Treg cells.
DISCUSSION
Immune responses in the intestine require a delicate balance
between effector and regulatory pathways and perturbation of
this network can result in chronic intestinal inflammation. IL-23
has been shown to play a key role in both innate and T cell medi-
ated chronic colitis in mouse models (Hue et al., 2006; Kullberg
et al., 2006; Uhlig et al., 2006b; Yen et al., 2006) and IL23R has
been identified as a risk gene in IBDs (Burton et al., 2007; Duerr
et al., 2006). However, precisely which cell types it works on to
drive the intestinal inflammatory response was not known.
Here, utilizing IL-23R-deficient CD4+ T cells, we demonstrated
that intestinal, but not systemic, inflammation required the direct
stimulation of CD4+ T cells by IL-23 and could not be mediated
by IL-23-driven innate immune or IL-23-independent T cell
responses alone. We further showed that IL-23 signaling in
T cells played a crucial role in their proliferation and accumula-
tion in the colon and promoted the emergence of IL-17A+IFN-g+
double-producing CD4+ T cells while inhibiting the induction
of Foxp3+ Treg cells in the gut. These data suggest that the
tissue-specific role of IL-23 in orchestrating intestinal inflamma-
tion is mediated through direct effects on T cells that promote
their accumulation and pathogenic effector function in the
intestine.
The inability of IL-23R-deficient T cells to accumulate in the
colon upon transfer into Rag1/ hosts, but their unimpaired
ability to mount inflammatory responses in the spleen and liver,
suggests that IL-23 signaling in T cells is not required for general
T cell reconstitution of lymphopenic mice but is specifically
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Figure 6. IL-23 Inhibits Intestinal iTreg Cell Generation via a Direct
Cell-Intrinsic Mechanism
(A and B) C57BL.6.Rag1/ mice were transferred with 1:1 mixtures of
CD45.2 (WT) + CD45.2+ (WT) or CD45.2 (WT) + CD45.2+(Il23r/)
CD4+CD45RBhi T cells. Mice were sacrificed upon development of clinical
signs of inflammation (8 weeks).
(A) The frequency of Foxp3+ cells among T cells in the colon was assessed by
intracellular flow cytometry.
(B) Representative FACS plots showing Foxp3 expression in CD4+ T cells in
the colon; numbers in quadrants represent frequencies. Data represent pooled
results from two independent experiments, n = 15 (WT + WT), n = 12 (WT +
Il23r/).
(C and D) Sublethally irradiated C57BL.6.Rag1/ mice were reconstituted
with 1:1 mixtures of CD45.2 (WT) + CD45.2+ (WT) or CD45.2 (WT) +
CD45.2+(Il23r/) bone marrow cells. The frequency of Foxp3+ cells among
CD4+ cells in the colon was assessed by intracellular FACS during steady state
(C) or during colitis induced by infection withHelicobacter hepaticus plus treat-
ment with a blocking IL-10R mAb (D). Data represent results from a single
experiment; n = 5–7 (WT + WT), n = 5–7 (WT + Il23r/ T cells).
(E) Colitis scores frommice in (A); data represent pooled results from two inde-
pendent experiments.
(F) Il10 mRNA levels and protein levels in supernatants after restimulation of
CD4+ T cells purified from the colons of C57BL.6.Rag1/ mice transferred
with WT or Il23r/ CD4+CD45RBhi T cells as described in Figure 1 (single
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Mechanistic analysis showed this was not due to impaired
migration but rather a reduction in the proliferation of effector
T cells locally in the colon. This proliferative defect was observed
among colonic Th17 and Th1 cells, explaining the reduction in
both Th1 and Th17 cell numbers in the colon in the absence of
IL-23R signaling in T cells. Recently, we have found that
STAT3-deficient T cells fail to mount either systemic or intestinal
inflammation in T cell transfer colitis (Durant et al., 2010). These
results suggest that IL-23 is a major mediator of STAT3 signaling
in T cells in the intestinal but not systemic immune compartment.
Our results also raise the possibility that the requirement for
RORgt expression in T cells for development of T cell transfer
colitis (Leppkes et al., 2009) reflects the known activities
of RORgt in promoting Il23r expression (Zhou et al., 2007) on
T cells.
In stark contrast to the inability of adoptively transferred
Il23r/ T cells to accumulate in the intestine, the presence of
WT T cells, in either the T cell cotransfer experiments or in the
mixed bone marrow chimeras, facilitated the efficient accumula-
tion of Il23r/ T cells in the colon. This suggests that an IL-23R-
sufficient T cell is required to initiate the inflammatory cascade
and produces factors in response to IL-23 that sustain the prolif-
eration and accumulation of IL-23R-deficient T cells. Such
signals may be of paramount importance in the context of
intestinal inflammation, for which IL-23-driven pathology is char-
acterized by the accumulation of both Th1 and Th17 cells in the
intestine (Hue et al., 2006; Izcue et al., 2008). These findings
contrast with those described in models of CNS inflammation,
where Th1 and Th17 cell responses are thought to be antago-
nistic. Furthermore, a cell-intrinsic role for IL-23R expression in
Th17 cell accumulation in the brain during EAE was recently
described, which could not be overcome by the presence of
WT T cells (McGeachy et al., 2009). Taken together, these data
indicate that the requirements for direct IL-23 signals in T cell
accumulation at inflammatory sites are likely to be context
dependent, modulated by the tissue environment and the pres-
ence of other inflammatory cells.
In addition to impaired accumulation in the intestine, Il23r/
T cells gave rise to significantly reduced frequencies of T cells
secreting IL-17A, but not IFN-g, compared to WT T cells. This
suggests a specific role for IL-23R signaling in T cells for the
differentiation, proliferation, or survival of Th17 cells. Similar
results have been observed in EAE models where IL-23 was
found to drive increased accumulation of Th17 cells (Awasthi
et al., 2009; McGeachy et al., 2009). Recent studies suggest
that Th17 cells exhibit flexibility of function and can modify their
phenotype, including acquisition of IFN-g production in
response to IL-12 or IL-23 in vitro or during induction of diabetes
and colitis (Bending et al., 2009; Lee et al., 2009). Notably,
IL-17A+IFN-g+ CD4+ T cells are prominent in T cell-dependent
colitis models (Hue et al., 2006; Kullberg et al., 2006) and havetransfer) or from recipients of 1:1 mixtures of WT + Il23r/ CD4+CD45RBhi
T cells as described above (cotransfer). Data represent pooled results from
two independent experiments (top, n = 7–10 per group) or from a single exper-
iment (bottom, n = 5 per group).
Bars represent the mean; each symbol represents an individual mouse; statis-
tical significance was determined with the Mann-Whitney test.
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patients (Annunziato et al., 2007; Cosmi et al., 2008). Our
results extend these studies to show that in the intestine the
emergence of IL-17A+IFN-g+ double-producing Th cells, but not
IL-17A+IFN-g Th cells, requires T cell-intrinsic IL-23 signaling.
Together, these results suggest that IL-23 is an important modi-
fier of the Th17 cell phenotype in the intestine, promoting the
emergence of IL-17A+IFN-g+ Th cells. The dependence of these
cells on IL-23 suggests they play an important role in pathogen-
esis. The ability of IL-23 to promote IFN-g expression in Th17
cells is T-bet dependent in vitro (Lee et al., 2009), raising the
possibility that in addition to driving conventional Th1 cell
responses, the requirement for T-bet in T cell transfer colitis
(Neurath et al., 2002) involves IL-23-dependent modulation of
the Th17 cell phenotype. Indeed, there is evidence of a role for
T-bet in the pathogenicity of Th17 cells in EAE (Yang et al., 2009).
Under homeostatic conditions, the intestine has been shown
to be a preferential site for the differentiation of Foxp3+ iTreg
cells (Coombes et al., 2005). Our previous work showed that
during intestinal inflammation, IL-23 could antagonize develop-
ment of Foxp3+ Treg cells, facilitating the development of intes-
tinal inflammation (Izcue et al., 2008). Whether IL-23 works
directly on T cells or indirectly through APC tomediate this effect
was not established. Here, we show that IL-23 inhibits the accu-
mulation of Foxp3+ Treg cells in the intestine through a direct cell
intrinsic mechanism. This effect was observed in T cell transfer
colitis as well as in lymphocyte-replete bone marrow chimeras
in the presence or absence of intestinal inflammation, indicating
that the effects of IL-23R signaling into T cells on Foxp3 expres-
sion are not secondary to a lack of inflammation or the lympho-
penic Rag1/ environment. Recently it has been shown that,
prior to differentiating into Th17 or Foxp3+ iTreg, T cells may
pass through a RORgt+Foxp3+ intermediate stage (Lochner
et al., 2008; Zhou et al., 2008). Such RORgt+Foxp3+ double posi-
tive cells are more frequent in the intestine raising the possibility
that IL-23 acts directly on these cells to promote Th17 differen-
tiation and inhibit induction of Foxp3+ Treg cells. Although
IL-23R deficiency was associated with impaired EAE, there
was no increase in the frequency of Foxp3+ Treg cells in the
CNS among Il23r/ T cells in mixed bone-marrow chimaeras
with active EAE (McGeachy et al., 2009). Differences in the
actions of IL-23 on Treg cells in the gut and CNS may reflect
the additional influence of themicrobiota which is known to influ-
ence accumulation of Treg in the intestine (Ivanov et al., 2008).
Alternatively, other STAT3 signaling cytokines such as IL-6 and
IL-21 may be more important negative regulators of Foxp3
expression outside the intestine (Bettelli et al., 2006; Korn
et al., 2007; Nurieva et al., 2007; Zhou et al., 2007). In contrast
with the induction of Foxp3+ Treg cells in the periphery, there
is evidence that in the tumor microenvironment, STAT3 signaling
through IL-23R expression increases Foxp3 and IL-10 expres-
sion by Treg cells (Kortylewski et al., 2009). These opposing roles
of IL-23R signaling on Foxp3 expression in the tumor and gut
may reflect differences in the tissue microenvironments or the
differentiation state of responding T cells. One possibility that
we favor is that in the intestine the effects of IL-23 are to restrain
iTreg cell development, whereas in the tumor microenvironment
IL-23 may act on established thymic-derived Treg cells to
enhance their function.286 Immunity 33, 279–288, August 27, 2010 ª2010 Elsevier Inc.Reduced colitogenic activity among Il23r/ T cells was also
associated with increased expression of IL-10. These results
are consistent with our earlier finding that IL-10 plays a functional
role in the amelioration of intestinal inflammation in Il23a/mice
(Izcue et al., 2008). By contrast with the cell-intrinsic role of
IL-23R in the negative regulation of Foxp3 expression, we found
that the presence of WT cells was sufficient to abrogate
increased IL-10 expression by Il23r/ T cells. The ability of
IL-23 to act through a cell-extrinsic mechanism to reduce
T cell-derived IL-10 may be a further pathway through which
IL-23 promotes intestinal inflammation. Further studies are
required to identify the molecular mechanism involved.
In summary, we describe a crucial role for IL-23-driven T cell
responses in the development of intestinal but not systemic
inflammation. Our findings underscore genetic studies that
pinpoint a role for IL-23R-mediated pathways in IBD pathogen-
esis (Burton et al., 2007; Duerr et al., 2006) and provide insight
into themechanism of action of IL-23 in vivo. Our results highlight
the dual nature of IL-23 activity on T cells and suggest that
blockade of IL-23will ameliorate intestinal inflammation by inhib-
iting the accumulation and pathogenic activity of helper T cells
and promotemucosal tolerance by facilitating expansion of iTreg
cells and production of IL-10.
EXPERIMENTAL PROCEDURES
Mice
Wild-type C57BL.6., C57BL.6.Il23r/, congenic B6.SJL-Cd45.1, and
C57BL.6.Rag1/ mice were bred and maintained under specific pathogen-
free conditions in accredited animal facilities at the University of Oxford and
Merck Research Laboratories. Experiments were conducted in accordance
with the UK Scientific Procedures Act of 1986. Mice were routinely screened
for Helicobacter spp. and were >6 weeks old when used.
Generation of Mixed Bone Marrow Chimeras
Bone marrow isolated from C57BL.6.or C57BL.6.6 Il23r/mice was mixed in
a 1:1 ratio with bone marrow taken from B6.SJL- Cd45.1 mice and injected
intravenously into gamma-irradiated (5.5 Gy, 550 rad) C57BL.6.Rag1/ recip-
ients and chimaeras were used in experiments >20 weeks after injection.
Transfer of Naive CD4+CD45RBhi T Cells
Naive CD4+CD45RBhi T cells were purified (>98%) from spleens of C57BL.6 or
C57BL.6 Il23r/ mice via FACS sorting as previously described (Izcue et al.,
2008) with a cell sorter (MoFlo; DakoCytomation). In cotransfer experiments,
C57BL.6 or C57BL.6 Il23r/ naive CD4+CD45RBhi T cells were mixed 1:1
with naive CD4+CD45RBhi T cells isolated from congenic B6.SJL-Cd45.1
mice. Naive T cell suspensions were washed in sterile PBS and sex-matched
Rag1/ recipient mice received 4 3 105 CD4+CD45RBhi T cells by intraperi-
toneal (i.p.) injection. For cotransfer experiments, 8 3 105 cells were trans-
ferred per mouse in one of the two experiments. For mice sacrificed on day
12 after transfer, 4 3 106 CD4+CD45RBhi T cells labeled with 5 mM CFSE
were transferred per mouse.
Assessment of Intestinal Inflammation
Mice were monitored regularly and sacrificed when symptoms of clinical
disease (significant weight loss and/or diarrhea) became apparent. Intestinal
inflammation was assessed as previously described (see ‘‘Assessment of
Intestinal Inflammation’’ in the Supplemental Experimental Procedures) (Izcue
et al., 2008).
Isolation of Leukocyte Subpopulations and FACS
Cell suspensions from spleen, MLN, and the lamina propria were prepared as
described previously (Uhlig et al., 2006a). Cells were surface stained for flow
cytometry with combinations of the following panel of antibodies: anti-CD4
Immunity
Direct IL-23 Signals into T Cells Drive Colitisconjugated to PerCp or FITC, anti-mouse TCR-b conjugated to APC, and anti-
CD45.2 conjugated to FITC. Intracellular staining was performed as follows:
cells were restimulated for 4 hr as previously described (Hue et al., 2006).
Cells were washed and incubated with anti-Fc receptor (anti CD16/32 from
eBioscience) to prevent nonspecific staining at 4C. Cells were washed and
stained for surface markers indicated above, washed again, and fixed
overnight in eBioscience Fix/Perm buffer at 4C. Cells were then washed
and then permeabilized in eBioscience Permeabilisation buffer for 1 hr at
4C, and subsequently, cells were stained with anti-IL-17A conjugated to
PE, anti-IFN-g conjugated to APC or FITC (both from BD Biosciences),
anti-Foxp3 conjugated to APC or FITC (from eBiosciences), and anti-Ki-67
conjugated to FITC (BD Biosciences) or appropriate isotype controls (BD
Biosciences) for 30 min at 4C. Cells were washed twice and acquired with
a FACSCalibur, FACSort (BD Biosciences), or Cyan (Dako), and analysis was
performed with FlowJo (Tree Star) software.
Cytokine Quantitation in Intestinal Tissues and Serum
Frozen samples of the proximal, mid, and distal colon were processed as
described previously (Hue et al., 2006) with homogenization performed with
a FastPrep 24 homogenizer (MP Biomedicals) with lysing matrix D beads
(MP Biomedicals). Colonic cytokines were measured with cytometric bead
assay (BD Biosciences) (TNF-a, IFN-g, and MCP-1) and normalized to protein
levels as determined by Bradford Assay (Bio-Rad). Alternatively cytokines
were quantified by RT-qPCR (Hue et al., 2006). For determination of IL-10
protein levels and gene expression, CD4+ T cells were purified from the colon
with a cell sorter (MoFlo; DakoCytomation) and cells were restimulated over-
night as above without Brefeldin A. Sequences for primers sets and probes
are described in Table S1. Ccr6, Ccr5, Ccr2, and Cxcr3 qPCR primer sets
are taken from PrimerBank (Spandidos et al., 2008, 2010; Wang and Seed,
2003). Serum cytokines (IL-17A, IL-22, TNF- a, IFN-g, MCP-1, and IL-6)
and IL-10 levels in supernatants of overnight cultures were assessed with
Flow Cytomix (Bender MedSystems) in accordance with the manufacturer’s
protocol.
Bacteria
Helicobacter hepaticuswas grown and used for colitis induction with concom-
itant administration of a blocking IL-10R mAb as previously described (see
‘‘Bacteria’’ in the Supplemental Experimental Procedures) (Buonocore et al.,
2010).
Statistics
The nonparametric Mann-Whitney test was used for assessment of statistical
significance (Olsen, 2003). Differences were considered statistically significant
when p < 0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at doi:
10.1016/j.immuni.2010.08.010.
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